Antiangiogenic therapies are cytostatic rather than cytotoxic and, therefore, do not simply decrease tumour sizes. Thus, traditional assessment of radiographic response according to MRI-based tumour-volume criteria can no longer be considered adequate. Instead, vessel-calibre MRI has emerged as a potential alternative—providing insight into vessel type and oxygenation status, and opening possibilities for clinical trial design and monitoring therapeutic response and outcomes.
- Kyrre E. Emblem
- Christian T. Farrar
- Rakesh K. Jain
